Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Open Access
- 14 March 2020
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12888-020-02530-2
Abstract
Prescription rates for long-acting injectable (LAI) antipsychotic formulations remain relatively low in Europe despite improved adherence over alternative oral antipsychotic treatments. This apparent under-prescription of LAI antipsychotics may have multiple contributing factors, including negative mental health practitioner attitudes towards the use of LAIs. The Antipsychotic Long acTing injection in schizOphrenia (ALTO) non-interventional study (NIS), conducted across several European countries, utilised a questionnaire that was specifically designed to address physicians’ attitudes and beliefs towards the treatment of schizophrenia with LAI antipsychotics. Exploratory principal component analysis (PCA) of feedback from the questionnaire aimed to identify and characterize the factors that best explained the physicians’ attitudes towards prescription of LAIs. Overall, 136/234 solicited physicians returned fully completed questionnaires. Physicians’ mean age was 48.5 years, with mean psychiatric experience of 20.0 years; 69.9% were male, 84.6% held a consultant position, and 91.9% had a clinical specialty in general adult care. Most physicians considered themselves to have a high level of clinical experience with LAI antipsychotics (77.2%), with an increased rate of LAI antipsychotics prescription over the last 5 years (59.6%). Although the majority of physicians (69.9%) declared feeling no difference in stress levels when offering LAI compared to oral antipsychotics, feelings of ‘no/more stress’ versus ‘less stress’ was found to influence prescription patterns. PCA identified six factors which collectively explained 66.1% of the variance in physician feedback. Multivariate analysis identified a positive correlation between physicians willing to accept usage of LAI antipsychotics and the positive attitude of colleagues (co-efficient 3.67; p = 0.016). The physician questionnaire in the ALTO study is the first to evaluate the attitudes around LAI antipsychotics across several European countries, on a larger scale. Findings from this study offer an important insight into how physician attitudes can influence the acceptance and usage of LAI antipsychotics to treat patients with schizophrenia.Keywords
Funding Information
- H Lundbeck A/S (-)
This publication has 46 references indexed in Scilit:
- Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaBMC Psychiatry, 2013
- Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisInternational Journal of Neuropsychopharmacology, 2013
- Psychiatric disorders of patients seeking obesity treatmentBMC Psychiatry, 2013
- Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEuropean Psychiatry, 2011
- Health professionals' attitudes to depot injection antipsychotic medication: a systematic reviewJournal of Psychiatric and Mental Health Nursing, 2010
- A Cross-Sectional Study of Patients' Perspectives on Adherence to Antipsychotic MedicationThe Journal of Clinical Psychiatry, 2008
- Depot and oral antipsychotics: patient preferences and attitudes are not the same thingJournal of Psychopharmacology, 2008
- Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up studyBMJ, 2006
- Defining and Assessing Adherence to Oral Antipsychotics: A Review of the LiteratureSchizophrenia Bulletin, 2005
- Why aren't depot antipsychotics prescribed more often and what can be done about it?Advances in Psychiatric Treatment, 2005